Skip to Content

Sarcoma Cancer Trials

​A091401: Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Patients with Metastatic or Unresectable Sarcoma
The purpose of this study is to see the good and bad effects of study drugs Nivolumab and/or ipilimumab in treating sarcoma.
Diagnosis: Sarcoma
Principal Investigator: Bruce Brockstein, MD
IRB Approval Number: EH15-366
Sponsor: Alliance for Clinical Trials in Oncology
Contact: Interested patients should contact research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment: Yes